BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Morgan Stanley initiates overweight on IPCA Lab
Company steadily growing India formulations. Expect further ramp- up in antimalarials. Company will continue to have a healthy return on equity at more than 20 per cent. IPCA is a preferred healthcare mid-cap stock.